Article Text

  1. E. Chan,
  2. S. Devaraj,
  3. I. Jialal
  1. Davis, Sacramento, 1University of Maryland


Inflammation plays a pivotal role in all stages of atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may participate in atherothrombosis. Hydroxymethylglutaryl coenzyme A (HMG Co-A) reductase inhibitors (statins) have documented a reduction in cardiovascular events in clinical trials. In addition to their beneficial effects on the lipoprotein profile, they lower CRP levels. The metabolic syndrome (MS) is a proinflammatory state with a constellation of risk factors that predict the development of cardiovascular disease. There is a paucity of data examining the effect of statins on inflammation in MS. Hence, the aim of this study was to test the effect of simvastatin (40mg/day, S-40) on inflammatory markers, namely hsCRP and monocytic cytokines (TNF-α, IL-6 and IL-1b) in patients with MS defined by NCEP-ATPIII in a randomized, double-blind, placebo (P) - controlled study over 8 weeks. HsCRP levels were assayed using a high sensitivity near infra red particle rate immunoassay. Monocytes were separated by negative magnetic separation and activated with lipopolysaccharide (LPS, 100 ng/mL) in presence and absence of mevalonate (250μM) and monocyte cytokines were assayed by sandwich ELISA. The coefficient of variation of the hsCRP and monocyte cytokine assays were ≤10%. There were no differences in age, gender, BMI, lipoprotein levels and inflammatory markers in the two groups at baseline. As expected, S-40 therapy resulted in a significant lowering of LDL cholesterol levels at both 4 and 8 weeks compared to placebo (34% reduction at 8 weeks, p≤0.0005). S-40 therapy also significantly decreased hsCRP levels at 4 and 8 weeks compared to placebo (36% median reduction at 8 weeks, p≤0.0005). Furthermore S-40 therapy compared to placebo resulted in a significant reduction in LPS-activated monocytic release of IL-6 and TNF at both 4 and 8 weeks (% median reduction at 8 weeks for IL-6 and TNF 55% and 39% respectively, p≤0.025). S-40 therapy failed to affect monocyte IL-1b release. In addition to there being no correlation between LDL cholesterol reduction and CRP reduction with S-40, co-incubation of monocytes with mevalonate did not reverse the inhibition of IL-6 and TNF seen with S-40. Thus, we show, for the first time, a direct anti-inflammatory effect of S-40 therapy on hsCRP and monocyte IL-6 and TNF in patients with MS. This has major implications in forestalling cardiovascular disease in this high risk group.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.